ATRS Stock
Price Chart
ATRS Financial and Trading Overview
stock price | |
Previous Close | 5.58 |
Open | 5.59 |
Bid | 5.58 x 308700 |
Ask | 5.59 x 312300 |
Day's Range | 5.58 - 5.59 |
52 Week Range | 3.11 - 5.6 |
Volume | 1.76M |
Avg. Volume | 5.23M |
Market Cap | 950.53M |
Beta (5Y Monthly) | 1.509313 |
PE Ratio (TTM) | 14.946524 |
EPS (TTM) | 0 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.95 |
ATRS Valuation Measures
Enterprise Value | 904.7M |
Trailing P/E | 14.946524 |
Forward P/E | 31.055555 |
PEG Ratio (5 yr expected) | 0.88 |
Price/Sales (ttm) | 5.1664553 |
Price/Book (mrq) | 6.751208 |
Enterprise Value/Revenue | 4.917 |
Enterprise Value/EBITDA | 28.957 |
Trading Information
Stock Price History
Beta (5Y Monthly) | 1.509313 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 5.6 |
52 Week Low | 3.11 |
50-Day Moving Average | 4.93 |
200-Day Moving Average | 3.92 |
ATRS Share Statistics
Avg. Volume (3 month) | 5.23M |
Avg. Daily Volume (10-Days) | 2.37M |
Shares Outstanding | 170.04M |
Float | 155.61M |
Short Ratio | 0.74 |
% Held by Insiders | 7.55% |
% Held by Institutions | 60.37% |
Shares Short | 7.28M |
Short % of Float | 4.34% |
Short % of Shares Outstanding | 4.27% |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2021 |
Most Recent Quarter (mrq) | December 31, 2021 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 25.16% |
Operating Margin (ttm) | 14.86% |
Gross Margin | 62.88% |
EBITDA Margin | 16.98% |
Management Effectiveness
Return on Assets (ttm) | 7.27% |
Return on Equity (ttm) | 31.39% |
Income Statement
Revenue (ttm) | 183.98M |
Revenue Per Share (ttm) | 1.09 |
Quarterly Revenue Growth (yoy) | 10.40% |
Gross Profit (ttm) | 115.7M |
EBITDA | 31.24M |
Net Income Avi to Common (ttm) | 46.29M |
Diluted EPS (ttm) | 0.374 |
Quarterly Earnings Growth (yoy) | -36.39% |
Balance Sheet
Total Cash (mrq) | 67.16M |
Total Cash Per Share (mrq) | 0.4 |
Total Debt (mrq) | 25.22M |
Total Debt/Equity (mrq) | 14.35 |
Current Ratio (mrq) | 2.957 |
Book Value Per Share (mrq) | 0.828 |
Cash Flow Statement
Operating Cash Flow (ttm) | 36.62M |
Levered Free Cash Flow (ttm) | -16590125 |
Profile of
Country | |
State | NJ |
City | Ewing |
Address | 100 Princeton South |
ZIP | 08628 |
Phone | 609 359 3020 |
Website | https://www.antarespharma.com |
Industry | Medical Instruments & Supplies |
Sector(s) | Healthcare |
Full Time Employees | 201 |
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.
Q&A For Stock
What is a current ATRS stock price?
ATRS stock price today per share is .
How to purchase stock?
You can buy ATRS shares on the exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ?
The stock symbol or ticker of is ATRS.
Which industry does the company belong to?
The industry is Medical Instruments & Supplies.
How many shares does have in circulation?
The max supply of shares is 0.
What is Price to Earnings Ratio (PE Ratio)?
PE Ratio is 0.00000000 now.
What was earnings per share over the trailing 12 months (TTM)?
EPS is 0 over the trailing 12 months.
Which sector does the company belong to?
The sector is Healthcare.
ATRS included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
- {{ link.label }} {{link}}